10-Q: CEL-SCI Reports Q3 2024 Results, Advances Multikine Confirmatory Study

CEL-SCI Corporation reported its financial results for the third quarter of 2024 and provided an update on its lead investigational therapy, Multikine, including plans for a confirmatory registration study.

Summary

• CEL-SCI Corporation reported a net loss of $20.8 million for the nine months ended June 30, 2024, and $6.9 million for the three months ended June 30, 2024.
• The company's research and development expenses decreased by 20% for the nine-month period and 18% for the three-month period compared to the same periods in 2023.
• General and administrative expenses also decreased by 4% for the nine-month period and 20% for the three-month period compared to the same periods in 2023.
• The company's cash and cash equivalents decreased to $384,652 as of June 30, 2024, from $4,145,735 as of September 30, 2023.
• CEL-SCI is planning a 212-patient confirmatory registration study for Multikine, focusing on a specific target population of head and neck cancer patients.
• The company expects to begin enrollment in the confirmatory study in Q4 2024 or Q1 2025 and reach full enrollment by Q2 2026.
• The estimated cost of the confirmatory study is approximately $30 million.

Sentiment

Score: 6

Explanation: The document presents positive clinical trial results for Multikine, but the company's financial situation is concerning with significant losses and low cash reserves. The need for additional capital raises uncertainty.

Positives

• The FDA has indicated that CEL-SCI can proceed with a confirmatory registration study for Multikine.
• The company has identified a specific target population for Multikine with a significant unmet medical need.
• Phase III study data showed a substantial survival benefit for the target population treated with Multikine.
• The company has completed a bias analysis for the target population, supporting the efficacy results.
• The planned confirmatory study is smaller and focused, increasing the likelihood of success.
• Multikine has shown no significant safety issues or toxicities in clinical trials.

Negatives

• The company has incurred significant net losses, with a net loss of $20.8 million for the nine months ended June 30, 2024.
• The company's cash position has decreased significantly to $384,652 as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and liquidity needs.
• The company is dependent on raising additional capital to fund its operations and the confirmatory study.
• The company's disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses.

Risks

• The company's ability to raise additional capital is uncertain and dependent on market conditions.
• There is no guarantee that the company will obtain regulatory approval for Multikine.
• The company's recurring losses and low cash position raise concerns about its ability to continue operations.
• The company's reliance on equity financing may dilute existing shareholders.
• The company's disclosure controls and procedures are not effective, which could lead to inaccurate financial reporting.

Future Outlook

CEL-SCI plans to commence a 212-patient confirmatory registration study for Multikine in Q4 2024 / Q1 2025, with full enrollment expected by Q2 2026, and will seek early approval after full enrollment. The company believes that the confirmatory study has a high likelihood of success based on the survival benefit observed in the Phase III study.

Management Comments

• Management believes that Multikine significantly extended life in the target patient population.
• Management believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study.
• Management believes that Multikine should be added to the standard of care for the target population if approved as a pre-surgical treatment.

Industry Context

The report highlights the growing market for cancer immunotherapies and positions Multikine as a unique therapy given before surgery, targeting a specific patient population with low PD-L1 expression, differentiating it from checkpoint inhibitors like Keytruda and Opdivo which are typically used after surgery and for patients with high PD-L1 expression.

Comparison to Industry Standards

• The document compares Multikine to checkpoint inhibitors like Keytruda and Opdivo, noting that those drugs are most effective in patients with high PD-L1 expression, while Multikine is targeted at patients with low PD-L1 expression.
• The document cites a Bloomberg report estimating the global cancer immunotherapy market to reach $196.45 billion by 2030, indicating the potential market size for Multikine.
• The document highlights that current standard of care for head and neck cancer provides only about a 50/50 chance of surviving five years, while Multikine could increase that survival rate to over 70% in the target population, based on Phase III data.
• The document notes that currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors.

Related Party Transactions

• Certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $80,620.
• The company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants held by officers and directors, extending the expiration dates by twenty-four months, resulting in a deemed dividend of approximately $659,455.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be concerned about the company's financial stability.
• Patients with head and neck cancer may benefit from the potential approval of Multikine.
• Creditors face increased risk due to the company's low cash position.

Next Steps

• The company plans to commence enrollment in the 212-patient confirmatory registration study in Q4 2024 / Q1 2025.
• The company expects to reach full enrollment in the confirmatory study by Q2 2026.
• The company will seek regulatory approval for Multikine following full enrollment of the confirmatory study.

Key Dates

Keywords

Multikine, Immunotherapy, Head and Neck Cancer, Clinical Trial, Confirmatory Study, FDA, PD-L1, Survival Rate, Hazard Ratio, Biotechnology